1st Quarter - Report

AMERICAN COLLEGE OF CARDIOLOGY for AMERICAN COLLEGE OF CARDIOLOGY

Firm
Client
Income
—
Expenses
$470,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Health care quality; physician and hospital quality; health care innovation; Patient Protection and Affordable Care Act/health care reform implementation; Affordable Care Act repeal/replace/reform efforts; unique device identifier policy and post-market surveillance for medical devices; clinical trial design; clinical data registries; HIPAA and registries; federal funding/appropriations for HHS, NIH, AHRQ, CDC, FDA, HRSA and the Childrens Hospital Graduate Medical Education payment program, the Prevention & Public Health Fund, medical research, and prevention; research and scholarly communication policy; healthy diet/lifestyle; implementation and oversight of 21st Century Cures Act; data blocking/interoperability of electronic data; health disparities; National Clinical Care Commission Act implementation; reduction/oversight of prior authorization and other administrative burdens; digital health/FDA pre-certification; cardiomyopathy education and awareness; peripheral arterial disease (PAD) education and awareness; research on valvular heart disease including the CAROL Act (HR 1193); VA Mission Act implementation; COVID-19 and implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act, the Families First Coronavirus Response Act , the Coronavirus Aid, Relief, and Economic Security Act, Coronavirus Provider Protection Act, Healthcare Workforce Resilience Act, and clinician mental health including the Dr. Lorna Breen Health Care Provider Protection Act (HR 1667/S 610); patient identification

Contacted: Medicare Payment Advisory Commission (MedPAC); Office of Management & Budget (OMB); Health & Human Services, Dept of (HHS); Agency for Healthcare Research & Quality (AHRQ); HOUSE OF REPRESENTATIVES; Natl Institutes of Health (NIH); Food & Drug Administration (FDA); SENATE; Centers For Disease Control & Prevention (CDC); White House Office; Centers For Medicare and Medicaid Services (CMS)

Bills named: H.R. 1193 (117th), H.R. 1667 (117th)

Medicare/Medicaid MMM

Medicare physician payment; new/alternative payment models; Medicare coverage, including coverage policies pertaining to transcatheter mitral valve repair, hospital payment of cardiovascular services; access to Medicare claims data; physician and hospital quality; electronic health record incentive program; clinical data registries; health care quality; medical imaging and prior authorization; the Stark Law and the in-office ancillary services exception; Medicare Access and CHIP Reauthorization Act implementation and oversight; Bipartisan Budget Act of 2015 and Medicare site of service policy; access to and supervision of Cardiac and Pulmonary Rehabilitation (HR 1956); graduate medical education policy including the Resident Physician Shortage Reduction Act of 2021 (HR 2256/S 834); oversight and implementation of the Protecting Access to Medicare Act of 2014, including Appropriate Use Criteria; physician-owned hospital policy; Affordable Care Act repeal/replace/reform efforts; COVID-19 public health emergency and the implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act, the Families First Coronavirus Response Act, the Coronavirus Aid, Relief, and Economic Security Act; Protecting Access to Post-COVID-19 Telehealth Act (HR 366)

Contacted: Medicare Payment Advisory Commission (MedPAC); Health & Human Services, Dept of (HHS); White House Office; Agency for Healthcare Research & Quality (AHRQ); Food & Drug Administration (FDA); Office of Management & Budget (OMB); Natl Institutes of Health (NIH); SENATE; Centers For Disease Control & Prevention (CDC); Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES

Bills named: H.R. 1956 (117th), H.R. 2256 (117th), H.R. 366 (117th)

Tobacco TOB

Tobacco use prevention and smoking cessation; FDA regulation of tobacco; electronic cigarettes and nicotine products; tobacco and electronic cigarette policy in House and Senate Appropriations

Contacted: Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); Natl Institutes of Health (NIH); White House Office; Centers For Disease Control & Prevention (CDC); Medicare Payment Advisory Commission (MedPAC); Office of Management & Budget (OMB); Agency for Healthcare Research & Quality (AHRQ); Health & Human Services, Dept of (HHS); SENATE

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.